Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence
J Clin Oncol
.
2016 Mar 10;34(8):777-9.
doi: 10.1200/JCO.2015.65.4368.
Epub 2016 Jan 19.
Authors
Sumanta K Pal
1
,
Neeraj Agarwal
2
,
Petros Grivas
3
,
Toni Choueiri
4
Affiliations
1
City of Hope Comprehensive Cancer Center, Duarte, CA
[email protected]
.
2
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
3
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
4
Dana-Farber Cancer Institute, Boston, MA.
PMID:
26786913
DOI:
10.1200/JCO.2015.65.4368
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemotherapy, Adjuvant
Cisplatin / therapeutic use
Cystectomy*
Humans
Neoadjuvant Therapy
Prospective Studies
Urinary Bladder Neoplasms / drug therapy*
Substances
Cisplatin